Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
92.06 USD | +2.87% | +1.31% | -4.52% |
Kurzporträt
Mitarbeiterzahl: 3 401
Umsatz nach Geschäftsbereich
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Innovative Therapies
100,0
%
| 2 096 | 100,0 % | 2 419 | 100,0 % | +15.42% |
Umsatz je Region
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
United States
31,9
%
| 684 | 32,6 % | 771 | 31,9 % | +12.72% |
Europe
27,7
%
| 651 | 31,1 % | 669 | 27,7 % | +2.82% |
Rest of World
19,4
%
| 312 | 14,9 % | 468 | 19,4 % | +50.28% |
Latin America
13,7
%
| 267 | 12,7 % | 332 | 13,7 % | +24.60% |
Global
7,4
%
| 182 | 8,7 % | 178 | 7,4 % | -2.47% |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Alexander Hardy
CEO | Chief Executive Officer | 56 | 01.12. |
Brian Mueller
DFI | Director of Finance/CFO | 50 | 01.12.02 |
Kevin Eggan
CTO | Chief Tech/Sci/R&D Officer | - | 05.10.20 |
Philip Lo Scalzo
CMP | Compliance Officer | - | 01.01.07 |
Chief Tech/Sci/R&D Officer | - | 01.11.08 | |
C. Guyer
CTO | Chief Tech/Sci/R&D Officer | 62 | - |
Stuart Bunting
CTO | Chief Tech/Sci/R&D Officer | - | 01.11.08 |
Henry Fuchs
CTO | Chief Tech/Sci/R&D Officer | 66 | 01.03.09 |
Director/Board Member | 70 | 16.05.05 | |
Traci McCarty
IRC | Investor Relations Contact | - | - |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 04.01.16 |
Director/Board Member | 70 | 16.05.05 | |
Randy Meier
CHM | Chairman | 65 | 14.12.06 |
Elaine Heron
BRD | Director/Board Member | 76 | 01.07.02 |
V. Lawlis
BRD | Director/Board Member | 72 | 01.06.07 |
May Kin Ho
BRD | Director/Board Member | 71 | 17.02.21 |
Mark Enyedy
BRD | Director/Board Member | 60 | 27.12. |
Robert Hombach
BRD | Director/Board Member | 58 | 29.09.17 |
Willard Dere
BRD | Director/Board Member | 70 | 18.07.16 |
Director/Board Member | 66 | 10.07.19 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 189 775 040 | 188 177 949 ( 99,16 %) | 0 | 99,16 % |
Unternehmenskontakt
BioMarin Pharmaceutical, Inc.
770 Lindaro Street
94901, San Rafael
+415 506 6700
http://www.biomarin.comKonzerngesellschaften
Name | Kategorie und Branche |
---|---|
BioMarin International Ltd.
BioMarin International Ltd. BiotechnologyHealth Technology BioMarin International develops and commercializes biopharmaceuticals. The company was founded on June 16, 2011 and is headquartered in Dublin, Ireland. |
Biotechnology
|
Sektor
Umsatz je Region
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
-4.52% | 16.98 Mrd. | |
-2.73% | 85.68 Mrd. | |
+4.08% | 41.4 Mrd. | |
-25.35% | 28.22 Mrd. | |
+54.31% | 24.64 Mrd. | |
-42.09% | 13.29 Mrd. | |
-17.77% | 11.66 Mrd. | |
-12.10% | 11.65 Mrd. | |
+0.75% | 8.18 Mrd. | |
+3.32% | 7.78 Mrd. |
- Börse
- Aktien
- 924801 Aktie
- Unternehmen BioMarin Pharmaceutical Inc.